Shanghai Junshi Biosciences Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in December 2012 in Shanghai as an innovation-driven biopharmaceutical company, Shanghai Junshi Biosciences (HKEX: 1877 / SSE: 688180) has rapidly expanded from early NMPA clinical trial approvals in 2015 for a Humira biosimilar and a May 2016 Lingang production base build to U.S. FDA IND clearance for JS001 (PD-1) in July 2017 and a January 2018 IND for JS101 (Pan‑CDK), culminating in an October 2024 NDA approval in China for ongericimab; today Junshi operates a whole-industry-chain model-R&D, manufacturing and commercialization-supported by approximately 2,500 employees across the United States and China and a diversified pipeline of over 50 drug candidates spanning cancer, autoimmune, metabolic, neurological and infectious diseases, with immuno‑oncology flagship toripalimab approved in over 35 countries and regions and revenue driven primarily by product sales while future income is underpinned by international approvals and pipeline value; its dual-listing and capital actions-such as the registration in June 2025 of a 2025 A Share Option Incentive Scheme granting 24,700,000 A Share Options to 226 participants and the September 2024 repurchase of 815,871 A Shares (0.0828%) for incentive plans-alongside inclusion in the CSI A500 Index in December 2024, reflect an ownership and governance structure designed to align stakeholders and scale production, including efforts to expand macromolecule fermentation capacity and reduce unit costs to enhance competitiveness in global markets.

Shanghai Junshi Biosciences Co., Ltd. (1877.HK): Intro

• Founded: December 2012 (Shanghai, China)
• Listing: Hong Kong Stock Exchange (ticker: 1877.HK)
• Therapeutic focus: monoclonal antibodies, bispecifics, small molecules and recombinant proteins
• Pipeline scale: diversified portfolio with multiple preclinical and clinical-stage programs (over 20 programs across modalities and indications)

• Major shareholders: institutional investors, strategic biotech/VC backers and public float on HKEX (significant insider/early‑investor stakes at time of listing).
• Governance: board of directors with R&D and commercial leadership; global development partnerships for select assets.

• Mission: to discover and deliver innovative therapeutics to address unmet medical needs in China and globally.
• Vision: build a globally competitive biopharma company through science‑driven innovation, robust clinical development and scalable manufacturing.
• Core values emphasize patient focus, scientific rigor, collaboration and long‑term value creation (Mission Statement, Vision, & Core Values (2026) of Shanghai Junshi Biosciences Co., Ltd.).

• Discovery: internal biologics and small‑molecule discovery teams, target validation and translational research.
• Preclinical & Clinical Development: staged IND submissions to NMPA and FDA; progression from Phase I to registrational trials for prioritized assets.
• Manufacturing: in‑house GMP capacity (Lingang Production Base) to support clinical and commercial supply; production scale‑up to support launches and partnerships.
• Regulatory Strategy: dual‑path approach pursuing both Chinese regulatory approvals and international (FDA/EMA) filings where strategic.
• Commercialization: direct commercialization in China for approved products; strategic partnerships or licensing for ex‑China markets.

• Product sales - revenue from commercialized therapeutics following regulatory approval (e.g., ongericimab after NDA approval in China).
• Partnerships & Licensing - upfronts, milestone payments and royalties from collaborations with multinational pharmas and biotech partners.
• Contract Manufacturing & Supply - internal manufacturing capabilities can generate CMO/CMO‑like revenue streams and lower COGS for in‑house launches.
• R&D Service Income & Grants - selective grants, government support or co‑development reimbursements for strategic programs.

Shanghai Junshi Biosciences Co., Ltd. (1877.HK): History

• Dual listing: HKEX: 1877 and SSE: 688180, providing cross-market liquidity and investor access.
• Employee base: approximately 2,500 employees across the United States and China as of 2025.
• Index inclusion: A Shares included in the CSI A500 Index in December 2024.

• Public shareholders: mix of institutional and individual investors across HK and Shanghai listings.
• Insider alignment: share option grants (24.7M A options) and repurchased shares earmarked for incentive plans strengthen management/employee alignment.
• Liquidity/access: dual-listing enables capital raising and broader investor base; inclusion in CSI A500 raises index-driven ownership.

• Develop and commercialize first-in-class and best-in-class biologics to address unmet medical needs in oncology, immunology, and infectious disease.
• Leverage cross-border R&D and commercialization capabilities to bring therapies from China to global markets.

• R&D-driven model: discovery and development of monoclonal antibodies, antibody-drug conjugates, and bispecifics through in-house research and collaborations.
• Revenue streams:
  • Product sales from approved therapeutics (domestic and export markets).
  • Milestone and royalty payments from partnerships and licensing agreements.
  • Research collaborations and co-development deals with global pharma.
• Capital strategy: uses public listings, share repurchases, and equity-based incentives to manage dilution, align stakeholders, and fund clinical pipelines.

Shanghai Junshi Biosciences Co., Ltd. (1877.HK): Ownership Structure

• Committed to providing patients with world-class, trustworthy, affordable and innovative drugs to meet unmet medical needs.
• Focus on original innovation to develop first‑in‑class and best‑in‑class therapeutics, with strong emphasis on novel biologics and immunotherapies.
• Positioned as a pioneer in translational medicine-accelerating laboratory discoveries into clinical applications.
• Adopts a whole‑industry‑chain approach covering R&D, manufacturing and commercialization to become a globally competitive biopharmaceutical company.
• Rapidly expanding its product pipeline across oncology, autoimmune, infectious disease and other therapeutic areas.
• Committed to scaling macromolecule fermentation capacity and lowering production costs to improve operational efficiency and margins.

• R&D-driven business model: discovery → preclinical → clinical development → regulatory approval → commercialization.
• Core revenue drivers: in‑market biologics (notably anti‑PD‑1 antibody toripalimab/Tuoyi in oncology and partnered commercialized assets), licensing and collaboration milestones, and contract manufacturing.
• Partnering strategy: out‑licensing and co‑development agreements (domestic and global) generate upfront payments, development milestones and tiered royalties.
• Manufacturing scale-up: internal biologics production (fermentation and downstream processing) lowers COGS and supports supply for both domestic sales and export/partner supply agreements.
• Pipeline commercialization: a broad clinical portfolio (multiple Phase II/III assets) provides medium‑term revenue visibility via new launches and label expansions.

• Pipeline breadth: >20 programs across discovery and clinical stages, with multiple assets in Phase II/III (oncology, autoimmune, infectious disease).
• Commercial revenue profile: established oncology biologic(s) driving majority of product sales; revenue growth tied to label expansions and partner launches.
• R&D spend intensity: typically 30-50% of revenue reinvested into R&D in high‑growth years to support multiple clinical programs and global trials.
• Manufacturing capacity expansion: significant capex invested in macromolecule fermentation and downstream facilities to reduce COGS and ensure supply security.
• Cash & liquidity: maintains a cash runway supported by product cash flows, milestone receipts from partners, and capital market access (H‑share listings and potential follow‑on offerings).

• Licensing deals and co‑development agreements provide upfront payments, phased clinical milestones, and royalties on sales.
• Commercial collaborations accelerate market access outside China and expand royalty income; supply agreements leverage internal manufacturing.
• Potential future revenue from biosimilars/biologics CDMO services as fermentation and downstream capacity is monetized.

Shanghai Junshi Biosciences Co., Ltd. (1877.HK): Mission and Values

• Diversified R&D pipeline: over 50 active drug candidates spanning oncology, autoimmune, metabolic, neurological and infectious disease programs.
• Whole-industry-chain integration: in-house discovery capabilities, clinical development teams, and manufacturing capacity to support both clinical supply and commercial launch.
• Original innovation focus: prioritizes first-in-class and best-in-class biologics, with an emphasis on novel modalities and target validation.
• Global workforce: approximately 2,500 employees across China and the United States supporting R&D, regulatory, manufacturing and commercial operations.

• Immuno-oncology leadership: toripalimab is China's first domestically developed anti-PD-1 monoclonal antibody and a core commercial anchor in Junshi's oncology franchise.
• Infectious disease response: active development and deployment of COVID-19 therapeutics including etesevimab (neutralizing antibody) and MINDEWEI® (approved formulation/brand), reflecting capability to pivot to pandemic needs.
• Cross-therapeutic diversification: programs in autoimmune, metabolic and neurological diseases to balance oncology cyclicality and broaden long-term growth vectors.

• Discovery & preclinical - internal target ID, antibody engineering and small-molecule chemistry groups drive early assets.
• Clinical development - global trial capability with partnerships and CROs to support multi-region registrational studies.
• Manufacturing - in-house GMP biologics production facilities enabling scale-up from pivotal trials to commercial supply.
• Commercialization - direct launch capability in China and partnered/commercial presence in selected overseas markets.

• Revenue mix: commercial sales driven primarily by toripalimab in oncology markets, supplemented by partnered program milestones and product royalties.
• Capital intensity: substantial R&D and manufacturing investments to sustain broad pipeline (~50+ candidates) and to support global registration efforts.
• Partnerships & licensing: strategic collaborations for regional commercialization and co-development to expand market access and share development risk.

• Collaborative R&D and regional licensing deals to accelerate international registrations and market entry.
• Use of strategic alliances to share late‑stage clinical costs and to access established commercial infrastructures outside China.

Shanghai Junshi Biosciences Co., Ltd. (1877.HK): How It Works

• R&D-driven discovery platform: in‑house capabilities span antibody discovery, cell line development, preclinical pharmacology and clinical trial execution across oncology, immunology, infectious disease and metabolic indications.
• Clinical development & regulatory: global clinical trial network and regulatory filings in China, the US, EU and other jurisdictions to convert candidates into approved products.
• Manufacturing & supply chain: vertically integrated biologics manufacturing (fermentation, downstream purification, fill/finish) with planned scale‑up to reduce COGS per unit and support global launches.
• Commercialization: direct sales force in China plus distribution/partner networks and licensing agreements to access >35 international markets.

• Pipeline breadth: Junshi reports a diversified pipeline of over 50 drug candidates across multiple modalities, creating multiple potential future revenue streams.
• Core product focus: monoclonal antibody toripalimab (PD‑1 inhibitor) is a major revenue driver; other commercialized assets include etesevimab (COVID‑19 neutralizing antibody, in certain territories) and MINDEWEI® (COVID‑19 therapy marketed in China/selected markets).
• Strategic partnerships: collaborations and licensing deals accelerate international approvals and distribution while sharing development costs and risks.

• Product sales: direct sales of approved biologics (toripalimab, MINDEWEI®, others) represent the bulk of current revenue.
• Licensing & milestone payments: upfronts, development and commercial milestones, royalties from regional partners add non‑sales income.
• Partnership revenue: collaboration income from co‑development or supply agreements with multinational biopharma companies.
• Future approvals: expected new approvals from the >50 candidate pipeline provide multi-year upside once launched.

• Expand indications for key biologics (e.g., label expansion of toripalimab) to increase addressable market per product.
• Geographic expansion-registrations and partner launches to monetize products in >35 countries/regions.
• Manufacturing scale‑up-raising fermentation capacity and process optimization to reduce COGS and improve gross margins.
• Portfolio diversification-moving from single‑product dependence toward multiple marketed biologics and near‑term launches from the pipeline.

Shanghai Junshi Biosciences Co., Ltd. (1877.HK): How It Makes Money

• Product sales: commercial sales of approved therapeutics (notably toripalimab/TUOYI in multiple indications) in China and international markets.
• Licensing & collaborations: upfronts, milestones and cost-sharing from partner agreements for global development and commercialization.
• Royalties: ongoing royalties from out-licensed products in territories where partners hold commercialization rights.
• Contract manufacturing & services: leveraging expanded macromolecule fermentation capacity to provide manufacturing services and lower per‑unit COGS.
• Government and public-health procurement: pandemic-related therapeutics (e.g., etesevimab, MINDEWEI®) and emergency use deployments.

• Toripalimab approved in over 35 countries and regions, forming a core global commercial franchise.
• Product approvals and regulatory submissions in the US and Europe have expanded the company's global footprint.
• Active COVID-19 therapeutic development includes etesevimab and MINDEWEI®, contributing to public-health revenue streams and strategic positioning.
• Strategic investments in macromolecule fermentation capacity aim to cut production costs and improve margins through economies of scale.
• Inclusion in the CSI A500 Index in December 2024 underscores the company's market presence and institutional visibility.

• Volume growth from toripalimab international uptake lifts product-sales revenue and provides repeat prescription streams.
• Milestone and licensing receipts from Western partners accelerate upfront cash inflows during late‑stage approvals and launches.
• Lowered COGS via expanded fermentation capacity improves gross margins on biologics over time.
• Diversification across indications and therapeutic areas reduces single-product concentration risk and supports longer-term revenue stability.